A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Status:
Suspended
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This research study is studying a pair of immunotherapies as a possible treatment for
malignant pleural mesothelioma.
The drugs involved in this study are:
- Durvalumab
- Tremelimumab